Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/RAD21_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/RAD21_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/RAD21_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/RAD21_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/RAD21_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/RAD21_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/RAD21_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/RAD21_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/RAD21_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00070591 | Oral cavity | LP | chromosome segregation | 117/4623 | 346/18723 | 7.61e-05 | 9.91e-04 | 117 |
GO:200125217 | Oral cavity | LP | positive regulation of chromosome organization | 36/4623 | 82/18723 | 1.09e-04 | 1.31e-03 | 36 |
GO:004578612 | Oral cavity | LP | negative regulation of cell cycle | 127/4623 | 385/18723 | 1.33e-04 | 1.53e-03 | 127 |
GO:004593012 | Oral cavity | LP | negative regulation of mitotic cell cycle | 83/4623 | 235/18723 | 1.62e-04 | 1.82e-03 | 83 |
GO:190198712 | Oral cavity | LP | regulation of cell cycle phase transition | 126/4623 | 390/18723 | 3.69e-04 | 3.64e-03 | 126 |
GO:000081911 | Oral cavity | LP | sister chromatid segregation | 70/4623 | 202/18723 | 9.20e-04 | 7.82e-03 | 70 |
GO:00458391 | Oral cavity | LP | negative regulation of mitotic nuclear division | 22/4623 | 48/18723 | 1.14e-03 | 9.32e-03 | 22 |
GO:190199112 | Oral cavity | LP | negative regulation of mitotic cell cycle phase transition | 62/4623 | 179/18723 | 1.76e-03 | 1.34e-02 | 62 |
GO:001094811 | Oral cavity | LP | negative regulation of cell cycle process | 95/4623 | 294/18723 | 1.80e-03 | 1.37e-02 | 95 |
GO:00517841 | Oral cavity | LP | negative regulation of nuclear division | 24/4623 | 56/18723 | 2.17e-03 | 1.58e-02 | 24 |
GO:190198811 | Oral cavity | LP | negative regulation of cell cycle phase transition | 80/4623 | 249/18723 | 4.63e-03 | 2.94e-02 | 80 |
GO:000630211 | Oral cavity | LP | double-strand break repair | 80/4623 | 251/18723 | 5.81e-03 | 3.46e-02 | 80 |
GO:004828511 | Oral cavity | LP | organelle fission | 145/4623 | 488/18723 | 6.02e-03 | 3.57e-02 | 145 |
GO:00988131 | Oral cavity | LP | nuclear chromosome segregation | 88/4623 | 281/18723 | 6.72e-03 | 3.91e-02 | 88 |
GO:00070881 | Oral cavity | LP | regulation of mitotic nuclear division | 39/4623 | 110/18723 | 7.45e-03 | 4.14e-02 | 39 |
GO:004578715 | Oral cavity | LP | positive regulation of cell cycle | 96/4623 | 313/18723 | 9.08e-03 | 4.85e-02 | 96 |
GO:003304422 | Oral cavity | EOLP | regulation of chromosome organization | 50/2218 | 187/18723 | 1.80e-08 | 7.94e-07 | 50 |
GO:000706311 | Oral cavity | EOLP | regulation of sister chromatid cohesion | 11/2218 | 21/18723 | 7.12e-06 | 1.37e-04 | 11 |
GO:004477222 | Oral cavity | EOLP | mitotic cell cycle phase transition | 81/2218 | 424/18723 | 8.32e-06 | 1.59e-04 | 81 |
GO:001063923 | Oral cavity | EOLP | negative regulation of organelle organization | 67/2218 | 348/18723 | 3.78e-05 | 5.21e-04 | 67 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RAD21 | SNV | Missense_Mutation | | c.1522G>C | p.Glu508Gln | p.E508Q | O60216 | protein_coding | tolerated(0.18) | probably_damaging(0.932) | TCGA-A2-A0EW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
RAD21 | SNV | Missense_Mutation | novel | c.1627N>T | p.Asp543Tyr | p.D543Y | O60216 | protein_coding | tolerated(0.06) | possibly_damaging(0.67) | TCGA-A7-A6VV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
RAD21 | SNV | Missense_Mutation | | c.121N>C | p.Val41Leu | p.V41L | O60216 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
RAD21 | SNV | Missense_Mutation | | c.268N>T | p.Arg90Trp | p.R90W | O60216 | protein_coding | deleterious(0) | benign(0.167) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RAD21 | SNV | Missense_Mutation | | c.1485N>T | p.Glu495Asp | p.E495D | O60216 | protein_coding | tolerated(0.4) | benign(0.005) | TCGA-C8-A134-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
RAD21 | SNV | Missense_Mutation | | c.1130N>G | p.Ala377Gly | p.A377G | O60216 | protein_coding | tolerated(0.25) | probably_damaging(0.978) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
RAD21 | insertion | Nonsense_Mutation | novel | c.1641_1642insAGAAGAATAAATTCTAAGTCTTAAACAACAACCTCAAT | p.Asp548ArgfsTer8 | p.D548Rfs*8 | O60216 | protein_coding | | | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RAD21 | SNV | Missense_Mutation | novel | c.185N>A | p.Gly62Glu | p.G62E | O60216 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A3Y4-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
RAD21 | SNV | Missense_Mutation | | c.1450N>C | p.Asp484His | p.D484H | O60216 | protein_coding | deleterious(0.04) | benign(0.157) | TCGA-EK-A2RN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
RAD21 | SNV | Missense_Mutation | novel | c.426N>C | p.Glu142Asp | p.E142D | O60216 | protein_coding | tolerated(0.15) | probably_damaging(0.956) | TCGA-JW-AAVH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |